<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3934">
  <stage>Registered</stage>
  <submitdate>31/05/2011</submitdate>
  <approvaldate>31/05/2011</approvaldate>
  <nctid>NCT01363752</nctid>
  <trial_identification>
    <studytitle>A Study Looking at Kidney Function in Kidney Transplant Recipients Who Are Taking Anti-rejection Medication Including Tacrolimus and With or Without Sirolimus.</studytitle>
    <scientifictitle>A Multicenter, Two Arm, Randomized, Open Label Clinical Study Investigating Renal Function in an AdvagrafÂ® Based Immunosuppressive Regimen With or Without Sirolimus in Kidney Transplant Patients</scientifictitle>
    <utrn />
    <trialacronym>ADHERE</trialacronym>
    <secondaryid>2010-019639-37</secondaryid>
    <secondaryid>PMR-EC-1212</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Kidney Transplantation</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Advagraf
Treatment: drugs - Mycophenolate Mofetil
Treatment: drugs - Sirolimus
Treatment: drugs - Corticosteroids

Active Comparator: Advagraf + MMF + Steroids - Without sirolimus

Experimental: Advagraf + MMF + Steroids + Sirolimus - With sirolimus; MMF withdrawn on Day 28; Sirolimus introduced on Day 28


Treatment: drugs: Advagraf
oral

Treatment: drugs: Mycophenolate Mofetil
oral

Treatment: drugs: Sirolimus
oral

Treatment: drugs: Corticosteroids
i.v. and oral

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Glomerular Filtration Rate (GFR) estimated by iohexol clearance at Week 52 post kidney transplantation</outcome>
      <timepoint>up to 1 year</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy failure - Composite endpoint defined as graft loss (re-transplantation, nephrectomy, death or dialysis ongoing at the study end) or subject withdrawal</outcome>
      <timepoint>up to 1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>GFR at Week 52 post kidney transplantation by Modification Diet in Renal Disease (MDRD) formula</outcome>
      <timepoint>up to 1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>GFR at Week 52 post kidney transplantation by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula</outcome>
      <timepoint>up to 1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Calculated creatinine clearance at Week 52 post kidney transplantation by Cockcroft and Gault formula</outcome>
      <timepoint>up to 1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of clinical acute rejection</outcome>
      <timepoint>up to 1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to clinical acute rejection</outcome>
      <timepoint>up to 1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of Biopsy Confirmed Acute Rejection</outcome>
      <timepoint>up to 1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Biopsy Confirmed Acute Rejection</outcome>
      <timepoint>up to 1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Subject survival</outcome>
      <timepoint>up to 1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Graft survival</outcome>
      <timepoint>up to 1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>New Onset Diabetes Mellitus (NODM) as per American Diabetic Association (ADA) criteria</outcome>
      <timepoint>up to 1 year</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  End stage kidney disease and a suitable candidate for primary renal transplantation or
             re-transplantation (unless the graft was lost from rejection within 6 months)

          -  Receiving a kidney transplant from a deceased or living (non Human Leukocyte Antigen
             [HLA] identical) donor with compatible ABO blood type

          -  Female subject of childbearing potential has a negative serum or urine pregnancy test
             at enrollment

          -  Female and male subjects agree to maintain highly effective birth control during the
             study and for 90 days after discontinuation of dosing with study drugs. A highly
             effective method of birth control is defined as those which result in a low failure
             rate (CPMP/ ICH/ 286/ 95 modified) of less than 1% per year when used consistently and
             correctly such as implants, injectables, combined oral contraceptives, some
             Intrauterine Devises (IUDs), sexual abstinence or vasectomized partner</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Receiving or having previously received an organ transplant other than a kidney

          -  Cold ischemia time of the donor kidney &gt; 30 hours

          -  Panel Reactive Antibody (PRA) &gt;20%

          -  Receiving a graft from a non-heart-beating donor other than of Maastricht category 3
             (withdrawal of support awaiting cardiac arrest)

          -  Significant liver disease, defined as having continuously elevated SGPT/ ALT and/ or
             SGOT/ AST and/ or total bilirubin levels = 2 times the upper value of the normal range
             of the investigational site or is receiving a graft from a hepatitis C or B positive
             donor

          -  Requiring initial sequential or parallel therapy with immunosuppressive antibody
             preparation(s)

          -  Requiring ongoing dosing with a systemic immunosuppressive drug prior to
             transplantation (other than minimal levels of immunosuppression following failure of
             previous transplantation without nephrectomy)

          -  Significant, uncontrolled concomitant infections and/ or severe diarrhea, vomiting,
             active upper gastro-intestinal tract malabsorption or active peptic ulcer

          -  Pregnant woman or breast-feeding mother

          -  Subject or donor known to be HIV positive

          -  Known allergy or intolerance to tacrolimus, macrolide antibiotics, corticosteroids,
             sirolimus, MMF or any of the product excipients or iodine

          -  Evidence of malignant disease within the last 5 years, not including non-malignant
             skin cancers

          -  Currently participating in another clinical trial, and/ or has taken an
             investigational drug within 28 days prior to enrollment

          -  Unlikely to comply with the visits scheduled in the protocol</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>853</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>5042 - New Lambton</hospital>
    <hospital>5043 - Perth</hospital>
    <postcode>NSW 2305 - New Lambton</postcode>
    <postcode>WA 6009 - Perth</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Innsbruck</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Linz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belarus</country>
      <state>Minsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Liege 1</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Brno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Ostrava - Poruba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Amiens Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Brest Cedex 2</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Clermont-Ferrand Cedex 1</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Creteil Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Dijon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Le Kremilin Bicetre Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris Cedex 15</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse Cedex 9</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Tours cedex 9</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Vandoeuvre Les Nancy Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bochum</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Erlangen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hann.Munden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Kiel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munchen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munster</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Palermo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Siena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Busan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Daegu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Maastricht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Katowice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Kemerovo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Omsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Vol'ginskiy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Alicante</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Santander</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Vizcaya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Tainan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taoyuan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Istanbul</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Astellas Pharma Inc</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to compare the effect of two anti-rejection therapy regimens on
      kidney function in kidney transplant recipients.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01363752</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Use Central Contact</name>
      <address>Astellas Pharma Europe Ltd.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>